Calidi Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CLDI | NIKI | CALC | GRI | BIVI | CNSP | |
|---|---|---|---|---|---|---|
| Market cap | 2.68M | 5.27M | 9.18M | 3.13M | 11.63M | 6.34M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.8 | — | -0.8 | -0.7 | -2.4 | -11.1 |
| Price/book | 0.5 | 0.1 | 1.5 | 0.3 | 1.0 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.88% | −87.43% | −90.10% | −96.73% | +11.61% | −33.30% |
| Today | −2.54% | −3.98% | −8.50% | −7.14% | −22.54% | −4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CLDI news ›Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn...
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor
Calidi Biotherapeutics, Inc. Announces Appointment of Corsee Sanders to Board of Directors and Member of the Audit Committee, Effective June 17, 2026
Calidi Biotherapeutics, Inc. announced the appointment of Corazon Sanders, Ph.D., to the Board of Directors, effective June 17, 2026 with a term expiring at the Company?s 2029 annual meeting of... announced the appointment of Corazon…
Certain Pre-Funded Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026.
These Pre-Funded Warrants will be under lockup for 46 days starting from... Certain Pre-Funded Warrants of Calidi Biotherapeutics, Inc are subject to a Lock-Up Agreement Ending on 2
Calidi Biotherapeutics Presents New Data On CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 At The T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics presented data at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing... Calidi Biotherapeutics presented…
Calidi Biotherapeutics, Inc. Enters into Lease Termination Agreement with 4475 Executive Drive LLC
On July 10, 2026, Calidi Biotherapeutics, Inc. entered into a Lease Termination Agreement with 4475 Executive Drive LLC with respect to that certain lease dated October 10, 2022, as modified by a... On July 10, 2026, Calidi…
Calidi Biotherapeutics, Inc. Enters Into New Lease For Office And Laboratory Space In San Diego
On July 10, 2026, Calidi Biotherapeutics, Inc. entered into a lease agreement with BP3-SD4 5580 Morehouse Drive LLC, a Delaware limited liability company , pursuant to which the Company will lease... On July 10, 2026, Calidi…
Calidi Biotherapeutics, Inc. Presents New Data On Cytotoxicity And IL-15 SA Expression In Human And Murine Tumor Cells
Calidi Biotherapeutics, Inc. presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development Conference in Boston, MA. The Company presented new data on its... presented on July 23, 2026, at the…
Calidi Biotherapeutics announces strategic partnership with Transferai
Calidi Biotherapeutics Inc: Calidi Biotherapeutics announces strategic partnership with Transferai to drive efficiencies in the IND submission process for CLD-401 using agentic Artificial... Biotechnology & Medical Research Calidi…
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split
Calidi Biotherapeutics will effect a 1-for-16 reverse stock split of its outstanding common stock, the company said late Monday. The stock is expected to begin trading on a split-adjusted basis... Biotechnology & Medical Research Calidi…
Calidi Biotherapeutics, Inc.: Relative Strength Chart - Stock NYSE
Compare Calidi Biotherapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time CLDI price, NYSE stock exchange Relative Strength Chart Calidi Biotherapeutics, Inc. Biotechnology & Medical Research All…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.